Table 3
Trends (2009-2012) and forecast (2013-2016) of market share by prescription volume and proportion of costs for targeted therapies among antineoplastic agents for eye cancer in Taiwan
| Market share by prescription volume (%) | Proportion of costs (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Time | Real value | Forecast (ARIMA) | Low 95% CI | UP 95% CI | Real value | Forecast (ARIMA) | Low 95% CI | UP 95% CI |
| 2009Q1 | 3.36 | 35.15 | ||||||
| 2009Q2 | 0.00 | 4.14 | −2.61 | 10.89 | 0.00 | 37.31 | −3.38 | 77.99 |
| 2009Q3 | 0.00 | 1.84 | −4.91 | 8.59 | 0.00 | 12.55 | −28.14 | 53.23 |
| 2009Q4 | 3.70 | 3.89 | −2.87 | 10.64 | 23.22 | 24.27 | −16.41 | 64.95 |
| 2010Q1 | 7.59 | 3.97 | −2.78 | 10.72 | 52.56 | 33.62 | −7.07 | 74.30 |
| 2010Q2 | 4.53 | 4.49 | −2.26 | 11.24 | 37.84 | 41.56 | 0.88 | 82.25 |
| 2010Q3 | 2.07 | 3.52 | −3.23 | 10.27 | 18.42 | 26.76 | −13.93 | 67.44 |
| 2010Q4 | 7.18 | 7.19 | 0.44 | 13.95 | 36.66 | 23.94 | −16.74 | 64.62 |
| 2011Q1 | 4.70 | 10.03 | 3.27 | 16.78 | 19.88 | 45.75 | 5.07 | 86.43 |
| 2011Q2 | 2.13 | 2.61 | −4.15 | 9.36 | 22.61 | 24.72 | −15.96 | 65.40 |
| 2011Q3 | 3.83 | 5.03 | −1.73 | 11.78 | 33.23 | 35.45 | −5.23 | 76.13 |
| 2011Q4 | 7.35 | 6.99 | 0.24 | 13.75 | 43.44 | 39.42 | −1.27 | 80.10 |
| 2012Q1 | 9.52 | 6.43 | −0.32 | 13.19 | 46.87 | 39.23 | −1.45 | 79.92 |
| 2012Q2 | 4.69 | 6.80 | 0.04 | 13.55 | 33.21 | 43.39 | 2.71 | 84.07 |
| 2012Q3 | 10.33 | 5.84 | −0.91 | 12.60 | 64.00 | 34.88 | −5.80 | 75.56 |
| 2012Q4 | 17.33 | 14.72 | 7.96 | 21.47 | 68.81 | 64.57 | 23.89 | 105.25 |
| 2013Q1 | 13.45 | 6.70 | 20.20 | 57.98 | 17.29 | 98.66 | ||
| 2013Q2 | 10.33 | 1.91 | 18.76 | 54.67 | 4.50 | 104.83 | ||
| 2013Q3 | 16.15 | 7.70 | 24.60 | 62.44 | 11.46 | 113.42 | ||
| 2013Q4 | 20.26 | 11.08 | 29.44 | 66.69 | 15.20 | 118.18 | ||
| 2014Q1 | 16.23 | 4.49 | 27.98 | 68.61 | 14.39 | 122.83 | ||
| 2014Q2 | 14.65 | 2.00 | 27.30 | 70.17 | 12.70 | 127.63 | ||
| 2014Q3 | 20.26 | 7.50 | 33.02 | 71.72 | 11.49 | 131.94 | ||
| 2014Q4 | 22.67 | 9.11 | 36.23 | 73.45 | 10.99 | 135.92 | ||
| 2015Q1 | 18.86 | 3.55 | 34.16 | 76.07 | 11.69 | 140.44 | ||
| 2015Q2 | 18.74 | 2.89 | 34.59 | 78.68 | 12.47 | 144.89 | ||
| 2015Q3 | 23.89 | 7.88 | 39.89 | 80.77 | 12.53 | 149.01 | ||
| 2015Q4 | 24.97 | 8.14 | 41.80 | 82.67 | 12.36 | 152.99 | ||
| 2016Q1 | 21.72 | 3.64 | 39.80 | 84.77 | 12.52 | 157.03 | ||
| 2016Q2 | 22.73 | 4.28 | 41.19 | 86.99 | 12.94 | 161.05 | ||
| 2016Q3 | 27.21 | 8.55 | 45.87 | 89.22 | 13.40 | 165.03 | ||
| 2016Q4 | 27.33 | 7.85 | 46.80 | 91.39 | 13.83 | 168.96 | ||
Market share by prescription volume (%)=number of prescription of targeted therapies/total number of prescription of all antineoplastic agents.Proportion of costs (%)=cost of targeted therapies/total cost of all antineoplastic agents. ARIMA model for market share by prescription volume:
ARIMA model for proportion of costs:
